Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Interim Data Indicate Multiantigen Cell Therapy in Solid Tumors 'Just Might Work'

The immuno-oncology company's findings are reviewed in a ROTH Capital Partners report. In a July 22 research note, ROTH Capital Partners analyst Tony Butler reported that "encouraging data" from Marker Therapeutics Inc.'s (MRKR:NASDAQ) Phase I trial, TACTO...
Streetwise Reports | July 24, 2019 |

Can NervGen keep a lid on explosive news?

Speculation of early “evidence” of successful proof-of-concept human trials sparks stock rallies Trial volunteers taking a placebo are offered the real deal in a follow-up trial as a “reward” The company&Clo...
Knox Henderson | March 20, 2024 |

Buzz on the Bullboards: Markets underperforming, or is the best yet to come?

So, the “September rally” didn’t really pan out as many indices hit lows not seen in months, but at least interest rates were kept firm for now, so that is some good news, right? Investors have been worried about the possibility o...
Jonathon Brown | September 28, 2023 |

Buzz on the Bullboards: Sizzling sector highlights

It has been a sizzling few days recently for most of North America, both weather-wise and for investing discussions. The markets face a rate hike in the U.S., ongoing inflation, rising oil and...
Jonathon Brown | June 30, 2022 |

First Helium Highlighting its Immediate Helium Opportunity

Welcome to the Market Herald Video Q&A podcast. I’m Brieanna McCutcheon.Ed Bereznicki is the President and CEO of First Helium and has joined us today to give us a brief update on ongoing and...
Brieanna McCutcheon | August 30, 2022 |

Syndax Pharma Shares Rise on $35M Capital Raise, Credit Line and Positive Phase 1/2 Leukemia ...

Syndax Pharma Shares Rise on $35M Capital Raise, Credit Line and Positive Phase 1/2 Leukemia Trial Results Syndax Pharmaceuticals' shares traded 30% higher after the company reported it expects to raise $35 million from a common stock offering from five instituti...
Streetwise Reports | February 3, 2020 |

IoT solutions company raises cleaning standards

The following is a transcription of the above video, and The Market Online Canada has edited it for clarity . Our next company is Visionstate Corp. (TSXV:VIS) , headquartered in Edmonton. The company is focused on delivering data-driven, innovative and sustainable ...
Ryan Dhillon | February 14, 2024 |

Buzz on the Bullboards: Eye of the Storm

With the big weeks for energy companies behind us and the cannabis sector ongoing, the last week of trading has felt like the eye of the storm. When you add political tensions ramping up in Washington and uncertain global markets, it makes sense that investors had a tough time...
Omri Wallach | November 13, 2019 |

Oil’s Ongoing Struggle at Multiple Resistances. Resolution Just Ahead?

Although crude oil futures moved a bit higher yesterday, the major resistance zone created by three gaps and the 61.8% Fibonacci retracement again stopped the buyers. A pullback followed, and the futures invalidated the earlier breakout above the previous peaks. Tog...
Nadia Simmons | December 9, 2019 |

Fulgent Genetics Hits 52-Week High After Posting 84% Q3 Revenue Increase

Fulgent Genetics shares traded more than 40% higher today after the company reported record revenue in Q3/19. The firm noted that it completed a record 20,697 billable tests in Q3/19, up 272% over the same period last year. After U.S. markets closed yesterday, Temple ...
Streetwise Reports | November 6, 2019 |
1 2 3 4 5 6 7 8 9 10 ...